Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

Coronary Artery Disease Clinical Trial

— VINCA-CKD  

Official title:

The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01012414
• Other study ID #: 09C.110
• Status: Terminated
• Phase: Phase 3
• First received: November 11, 2009
• Last updated: May 13, 2014
• Start date: January 2010
• Est. completion date: May 2011

Study information

• Verified date: May 2014
• Source: Thomas Jefferson University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.

Description:

Vitamin D deficiency is common and has been associated with an increased risk of heart disease. In patients with the combination of kidney disease and heart disease, inflammation is thought to contribute to a high rate of cardiac events. Less is known about the effects of vitamin D supplementation on certain tests associated with inflammation in the body.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and non-pregnant, non-lactating women greater than 18 years of age

• Able to given informed consent and complete scheduled visits

• History of established coronary artery disease (CAD)as defined by coronary stenosis in one or more vessels greater than or equal to 70% by coronary angiography or CT angiogram OR abnormal stress test (at least medium-sized, moderate reversible defect) OR a presence of a CAD risk equivalent as defined by the National Cholesterol Education Panel (NCEP)III as: Framingham risk score = 20%, diabetes, or peripheral arterial disease(4)

• High Sensitivity C-reactive Protein (hs-CRP) = 2.0 mg/L

• History of stage 3 or 4 chronic Kidney disease (CKD) defined as an glomerular filtration rate (eGRF) by the Modification of Diet in Renal Disease (MDRD) formula of 15-60 mL/min/1.73 m2

• Low level of serum 25-hydroxyvitamin D (<30ng/mL)

• Evidence of secondary hyperparathyroidism defined as intact parathyroid hormone (iPTH) level > 70 pg/mL

• Stable dose of statin and/or other lipid lowering therapy (ie: ezetimibe, fibrates, bile acid sequestrants nicotinic acid, fish oil) for 12 weeks prior to enrollment without known plans for change to current therapy during the study period

Exclusion Criteria:

• History of myocardial infarction, stroke, or cardiac surgery within 6 months of enrollment

• History of carotid artery surgery

• Planned cardiovascular surgery or procedure, with the exception of permanent pacemaker placement, in the next 18 months.

• Use of vitamin D or calcium supplementation within the past 12 weeks with the exception of calcium containing phosphate binders and a daily multivitamin containing = 400 IU of vitamin D

• Hypercalcemia (as defined by the laboratory upper limit of normal ) or hyperphosphatemia (= 5.5 mg/dL)

• Plan to initiate renal replacement therapy (dialysis) during the study

• History of left ventricular systolic dysfunction with an ejection fraction <50% or history of New York Heart Association (NYHA)functional Class II-IV congestive heart failure

• Uncontrolled blood pressure, defined as systolic blood pressure greater than 160 mmHg and diastolic blood pressure greater than 100 mm Hg at the screening visit

• Uncontrolled diabetes, defined as hemoglobin A1C = 10.0

• History of any surgery within the past 3 months or known to be planned during the study period

• History of malignancy within the past 5 years with the exception of non-melanoma (ie:

squamous cell or basal cell) skin cancer

• History of a known systemic or pulmonary inflammatory condition (including rheumatoid arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease, pulmonary fibrosis, sarcoidosis, Wegener's granulomatosis, Goodpasture's disease)

• History of renal or other organ transplant and/or immunosuppressed state (ie immunosuppressive therapy or condition such as HIV)

• History of any other condition, that in the opinion of the investigators renders it unsafe for the subject to be enrolled

• For woman able to become pregnant, unwillingness to use birth control

• Participation in another clinical trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Avitaminosis
• Chronic Kidney Disease
• Coronary Artery Disease
• Coronary Disease
• Hyperparathyroidism
• Hyperparathyroidism, Secondary
• Hypovitaminosis D
• Kidney Diseases
• Myocardial Ischemia
• Renal Insufficiency, Chronic
• Rickets
• Secondary Hyperparathyroidism
• Vitamin D Deficiency

Intervention

Drug:
• paricalcitol
2 mcg oral paricalcitol daily
• placebo
placebo

Locations

Country	Name	City	State
United States	Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Thomas Jefferson University	Abbott

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in High Sensitivity-C Reactive Protein (Serum)		1 year	No
Secondary	Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A		1 year	No
Secondary	Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure.		1 year	No
Secondary	Effect on Carotid Intima-media Thickening (CIMT)		1 year	No